Abstract: The present disclosure is concerned with small molecule modulators of KLF15 signaling useful for treating various disorders such as, for example, kidney disease (e.g., chronic kidney disease), heart disease, obesity, or a neurodegenerative disorder (e.g., amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: The present invention includes a method for generating a three-dimensional model of a bone. The method may further include generating a cut plan for excavating a portion of the bone according to the cut plan to allow the insertion of a custom implant. In a particular arrangement, the method may includes excavating the bone with an autonomous extremity excavator utilizing the cut plan generated by a processor. In a further arrangement, the method may include generating a digital model of a custom implant and generating, using the digital model, a physical model sharing the same dimensions as the digital module using manufacturing device.

Abstract: The present disclosure relates generally to the use of sphingolipid-metabolizing proteins to mitigate or minimize tissue damage resulting from injury or from disease, for example, pulmonary arterial hypertension (PAH) when the sphingolipid-metabolizing protein is delivered via expression from an Anc80 vector.

Abstract: A tibial tray system for a resurfaced proximal portion of a tibia for a knee replacement for a patient includes a tibial tray and at least one screw. The tibial tray includes a body having a superior portion, and an inferior tibia-engaging portion having a peripheral inferiorly-extending portion receivable in the at least one cavity formed in the periphery of the resected cancellous bone surface of the tibia of the patient. In some embodiments in the total knee replacement, a greater portion of a shearing force acting transversely on the tibial tray and the resected portion of the proximal portion of the tibia of the patient is resisted by the at least one inferiorly-extending wall compared to a portion of the shearing force being resisted along the center inferior surface of the tibial tray and the resected cancellous bone surface. The screw inhibits lift-off.

Abstract: Disclosed herein are controlled release compositions comprising riluzole and the uses thereof.

Abstract: The present invention provides methods of diagnosing, treating, and monitoring the progression of inflammatory bowel disease in a subject, including, for example, by monitoring ROR?t+Th or ROR?t+Treg cell levels and treating the subject accordingly.

Abstract: Embodiments of the invention describe to methods of diagnosing, classifying, and/or identifying a patient's risk of developing graft versus host disease, including severe or lethal graft versus host disease, after receiving hematopoietic cellular transplantation, a transfusion or a transplantation, but before the onset of clinical symptoms.

Abstract: Disclosed herein are methods for diagnosing acute cellular rejection (ACR) of an allograft by analysis of predictive gene sets and kits for practicing these methods.

Abstract: Disclosed herein are gene signature sets expressed by kidney allograft recipients prior to transplant that determine the risk for acute rejection (AR) post-transplant and methods of using the gene signature sets for identifying renal allograft recipients at risk for acute rejection. Also disclosed herein are kits for use in the invention which comprise primer pairs for the gene signature sets.

Abstract: A method includes obtaining, via one or more processors, three-dimensional data representing a patient's bone, obtaining, via the one or more processors, three-dimensional data representing at least portions of a patient specific bone jig, the patient specific bone jig having an inner surface portion matched to an outer surface portion of the patient's bone, obtaining, via the one or more processors, image data representing the at least portions of the patient specific bone jig registered to the patient's bone, and generating, via the one or more processors, data representing a location and an orientation of the patient's bone based on the obtained image data, the obtained three-dimensional data representing the patient specific bone jig, and the obtained three-dimensional data representing the patient's bone. In another embodiment, a patient specific bone jig with predetermined spatial indicia registered to a portion of the patient's bone may be employed with point sampling.

Abstract: The present application relates to a nucleic acid molecule comprising a first nucleic acid sequence comprising at least a portion of a 5? untranslated region (5? UTR) of a carboxylesterase gene and a second nucleic acid sequence encoding a protein of interest, where the second nucleic acid sequence is heterologous to and operatively coupled to the first nucleic acid sequence. Also disclosed are methods of expressing a protein of interest in a target cell, methods of treating subject for cardiac ischemia or hepatic ischemia, and methods of identifying a nucleic acid sequence capable of selectively enhancing translation of a heterologous protein of interest in a target cell.

Abstract: Systems and methods for determining monitoring compliance are provided. Each element in a plurality of data elements is obtained from a medical device connected to a corresponding subject in a first plurality of subjects and interrogated to determine a condition of the device or subject. A medical code and timestamp for evaluation of the device or subject is recorded in the subject's medical record. A determination is made for each epoch in a plurality of epochs, for each subject in a second plurality of subjects, whether the medical code is recorded in the subject's medical record for the epoch by evaluating the time stamps and codes in the medical records. A compliance counter is advanced when a medical record includes the code for a respective epoch and otherwise a noncompliance counter is advanced. Responsive to a compliance request, compliance information or suggested treatment options are provided based on the counters.

Abstract: The present invention is directed to kinase inhibitor compounds having the following structure: or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, X, n, R3, Y, Z, R4, R5, R6, and = are as defined herein. The present invention also relates to compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

Abstract: Methods for designing heterobifunctional small molecules which selectively degrade/disrupt CDK4/6 and compositions and methods of using such degraders/disruptors to treat CDK4/6-mediated cancer are provided.

Abstract: In one aspect, provided herein are recombinant neuraminidases comprising an ectodomain of influenza virus neuraminidase with amino acid substitutions or insertions of cysteines in the stalk domain to generate a more stable, tetrameric influenza virus neuraminidase. In specific embodiments, the influenza virus neuraminidase further comprises influenza virus neuraminidase transmembrane and cytoplasmic domains. In another aspect, provided herein are recombinant neuraminidase comprising a globular head domain of influenza virus neuraminidase and a tetramerization domain, wherein the recombinant neuraminidase lacks influenza virus neuraminidase stalk, transmembrane and cytoplasmic domains. In another aspect, provided herein are methods of immunizing against influenza virus using such recombinant neuraminidases or compositions thereof.

Abstract: A genus of bicyclic inhibitors of CBX chromodomains is disclosed. The compounds are of the following genus: The compounds inhibit CBX proteins and, as a consequence, they are useful for treating prostate cancer, ovarian cancer, and B-cell lymphoma.

Abstract: Embodiments of the present disclosure pertain generally to head and neck squamous cell carcinomas (HNSCCs) related to human papillomavirus subtype 16 (HPV16) infections. More particularly, the present disclosure provides novel immunogenic epitopes from HPV16 E2, E6 and E7 antigens restricted by common human leukocyte antigen (HLA) alleles for the diagnosis and treatment of HNSCC. The HPV16 epitopes identified in the present disclosure can be used in combination with blockade of HPV16+ HNSCC-specific checkpoints for targeted immunotherapy.

Abstract: The present invention includes a method for generating a three-dimensional model of a bone and generating a cut plan for excavating a portion of the bone according to the cut plan to allow the insertion of a custom implant. In a particular arrangement, the method also includes excavating the bone with an autonomous extremity excavator utilizing the cut plan generated by a processor. In a further arrangement, the method includes generating a digital model of a custom implant and generating, using the digital model, a physical model sharing the same dimensions as the digital module using manufacturing device.

Abstract: Methods for designing bivalent compounds which selectively degrade/disrupt EZH2 and compositions and methods of using such degraders/disruptors to treat EZH2-mediated cancer are provided.

Abstract: A genus of dihydropyridine chemical modulators of synaptojanin is disclosed. These modulators are selective inhibitors of synaptojanin 1 and may be used to treat cognitive impairment or traumatic brain injury, including promoting regeneration in cases of traumatic brain injury, or for treating neurodegenerative disorders.